Salarius Pharmaceuticals, Inc. (SLRX)
SLRX Stock Price Chart
Explore Salarius Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze SLRX price movements and trends.
SLRX Company Profile
Discover essential business fundamentals and corporate details for Salarius Pharmaceuticals, Inc. (SLRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Jan 2015
Employees
2.00
Website
https://www.salariuspharma.comCEO
David J. Arthur
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
SLRX Financial Timeline
Browse a chronological timeline of Salarius Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 12 Nov 2025
Stock split effective on 18 Aug 2025
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Aug 2025
EPS came in at -$6.75 surpassing the estimated -$33.00 by +79.55%.
Earnings released on 14 May 2025
EPS came in at -$15.44 surpassing the estimated -$36.00 by +57.11%.
Earnings released on 21 Mar 2025
EPS came in at -$9.90 surpassing the estimated -$34.65 by +71.43%, while revenue for the quarter reached $4.43K .
Earnings released on 14 Nov 2024
EPS came in at -$11.39 falling short of the estimated -$2.40 by -374.58%.
Earnings released on 9 Aug 2024
EPS came in at -$35.53 surpassing the estimated -$803.60 by +95.58%.
Stock split effective on 17 Jun 2024
Shares were split 1 : 8 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 May 2024
EPS came in at -$49.18 surpassing the estimated -$803.60 by +93.88%.
Earnings released on 22 Mar 2024
EPS came in at -$26.39 surpassing the estimated -$121.14 by +78.22%, while revenue for the quarter reached $17.89K .
Earnings released on 9 Nov 2023
EPS came in at -$77.96 surpassing the estimated -$128.34 by +39.26%.
Earnings released on 10 Aug 2023
EPS came in at -$171.51 falling short of the estimated -$151.12 by -13.49%.
Earnings released on 11 May 2023
EPS came in at -$267.47 falling short of the estimated -$237.48 by -12.63%.
Earnings released on 27 Mar 2023
EPS came in at -$339.43 falling short of the estimated -$248.28 by -36.71%.
Earnings released on 10 Nov 2022
EPS came in at -$296.25 surpassing the estimated -$341.83 by +13.33%.
Stock split effective on 17 Oct 2022
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Aug 2022
EPS came in at -$269.87 surpassing the estimated -$329.84 by +18.18%.
Earnings released on 12 May 2022
EPS came in at -$389.81 falling short of the estimated -$2.25 by -17.22K%.
Earnings released on 10 Mar 2022
EPS came in at -$269.87 surpassing the estimated -$299.85 by +10.00%.
Earnings released on 4 Nov 2021
EPS came in at -$239.88 surpassing the estimated -$269.87 by +11.11%.
Earnings released on 5 Aug 2021
EPS came in at -$209.90 falling short of the estimated -$179.91 by -16.67%, while revenue for the quarter reached $571.39K , beating expectations by +0.07%.
Earnings released on 12 May 2021
EPS came in at -$179.91 falling short of the estimated -$1.25 by -14.29K%, while revenue for the quarter reached $1.27M , missing expectations by -7.38%.
Earnings released on 18 Mar 2021
EPS came in at -$299.85 , while revenue for the quarter reached $1.48M .
Earnings released on 11 Nov 2020
EPS came in at -$299.85 falling short of the estimated -$2.50 by -11.89K%, while revenue for the quarter reached $1.38M , meeting expectations.
SLRX Stock Performance
Access detailed SLRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.